- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Prostate Cancer | Clinical
Roundtable Discussion: Therapeutic Sequencing for Metastatic Castration-Resistant Prostate Cancer
December 07, 2021
Six months after a 75-year-old patient with castration-resistant prostate cancer shows undetectable PSA, the patient developed new hip pain and urinary frequency.
The Impact of Apalutamide Approval on the CSPC Landscape
December 03, 2021
Daniel P. Petrylak, MD, discusses the impact of the approval of apalutamide in the metastatic castration-sensitive prostate cancer setting.
Part 2: SPARTAN Trial Shows Efficacy of Apalutamide for CRPC
December 02, 2021
During a live virtual event, Eleni Efstathiou, MD, PhD, discussed the phase 3 SPARTAN trial of apalutamide in patients with castration-resistant prostate cancer.
Part 1: Guidelines and Recommendations for Treating nmCRPC
November 29, 2021
During a live virtual event, Eleni Efstathiou, MD, PhD, discussed the recommended approach to front-line treatment of castration-resistant prostate cancer.
Novel Cabazitaxel Formulation Shows Promise for Metastatic Prostate Cancer
November 29, 2021
Efficacy signals have been shown in 100% of patients with metastatic prostate cancer treated with a new formulation of cabazitaxel.
Mitigating Androgen Deprivation Therapy Cardiovascular Risk Factors in nmCRPC
November 22, 2021
Alicia K. Morgans, MD, PhD, discusses how to handle cardiovascular risk factors associated with androgen deprivation therapy in men with non-metastatic castration-resistant prostate cancer.
Sequencing Therapy for Metastatic Castration-Resistant Prostate Cancer
November 17, 2021
In season 2, episode 9 of Targeted Talks, Sandy Srinivas, MD and Nicholas J. Vogelzang, MD, discuss he optimal sequencing of therapies for a specific patient with metastatic castration-resistant prostate cancer.
No-Shave November: The Benefits of the Transperineal Versus Transrectal Approach to Prostate Cancer Biopsy
November 16, 2021
Matthew J. Allaway, DO, discusses the need for a safe, precise and efficient option for performing prostate cancer biopsies via the transperineal approach and the limitations with the current standard of care, which is the transrectal approach, during No-Shave November awareness month.
Roundtable Discussion: Experts Look at Treatment Options for Patients With Metastatic Castration-Resistant Prostate Cancer
November 16, 2021
A 75-year-old man presented with intermittent right hip pain, but his physical examination was unremarkable and he had an ECOG performance score of 1. Two oncologists lead a discussion about the patient's case.
Carthon Discusses Testing and Chemotherapy Vs Targeted Therapy in CRPC
November 16, 2021
A group of oncologists led by Bradley C. Carthon, MD, PhD, discussed clinical work-up, treatment, and follow-up for a 75-year old patents with castration-resistant prostate cancer.